Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-85.20M | $-2.04 |
Social Signal Score
Earnings
Typical surprise -145.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.98 vs $-0.78miss
- Wed, Jun 3$-21.83 vs $-5.98miss
Estimates and results for AVLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
AVLNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·3d ago·Neutral
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress, including data modeling AP01 lung tissue distribution Ended the second quarter of 2026 with $413.5 million in cash, cash equivalents and marketable securities; cash runway projected into 2029 BOSTO
View source ↗